Latest Hotspot

Connect Biopharma reports positive Phase 2b results for Rademikibart in moderate to severe adult asthma

21 December 2023
3 min read

Connect Biopharma Holdings Limited, an international biopharmaceutical firm engaged in the clinical advancement of treatments aimed at enhancing the well-being of individuals suffering from persistent inflammatory conditions, has declared the successful initial outcomes from an international Phase 2b study. This study assessed the effectiveness and safety profile of rademikibart in treating adults experiencing moderate to severe persistent asthma.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The international Phase 2b research encompassed a broad-based, multi-institutional, randomized, double-masked, placebo-managed scheme executed across 79 locations spanning the United States, Poland, Hungary, China, and South Korea. A total of 322 participants were distributed in equal fractions of 1:1:1 to receive either rademikibart at a dose of 150 mg biweekly following an initial 600 mg dosage, rademikibart at 300 mg biweekly post an initiating dose of 600 mg, or a placebo. The majority, approximating two-thirds, of the participants who underwent randomization received treatment within the U.S.

While the research wasn't primarily designed to identify variances in flare-ups, the administration of rademikibart exhibited positive indications of diminishing such incidents. Over the course of the 24-week investigation, the placebo arm recorded more than half of the total exacerbations. Further, both dosages of rademikibart seemed to contribute to a considerable delay in the occurrence of the initial exacerbation when compared to the placebo.

Dr. Zheng Wei, who is a co-founder and the Chief Executive Officer at Connect Biopharma, expressed excitement regarding the Phase 2b trial outcome. “The international findings manifest a statistically significant and consistent enhancement in pulmonary capability," Zheng Stated. "The data showcases that rademikibart, administered at both the higher and lower doses, was effective starting from the very first week of treatment."

Zheng added, "The favorable outcomes across the globe synergize with the optimistic findings from the crucial trial for atopic dermatitis held in China. These combined results enhance the prospect of rademikibart emerging as an industry-leading new-generation anti-IL-4Rα antibody for the treatment of Th2-axis-driven illnesses."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of December 19, 2023, there are 47 investigational drugs for the IL-4Rα target, including 73 indications, 70 R&D institutions involved, with related clinical trials reaching 420, and as many as 5326 patents.

Rademikibart shows potential as a therapeutic option for various diseases within the specified therapeutic areas. However, further research and clinical trials are needed to establish its safety and efficacy. The drug's progress to Phase 2 trials suggests that it has shown promising results thus far, but it is important to await further data and analysis to determine its ultimate potential in the pharmaceutical market.

What is post marketing research?
"What" Series
2 min read
What is post marketing research?
21 December 2023
post marketing research of drugs refers to the research on the use and effect of drugs following a specific research scheme after they are approved for marketing.
Read →
GigaGen Receives Authorization from FDA to Initiate Phase 1 Study of Cancer Drug GIGA-564 for Solid Tumor Treatment
Latest Hotspot
3 min read
GigaGen Receives Authorization from FDA to Initiate Phase 1 Study of Cancer Drug GIGA-564 for Solid Tumor Treatment
20 December 2023
GigaGen Inc. has announced FDA approval for its IND application. This permits the start of a Phase 1 trial to evaluate GIGA-564's effectiveness in treating diverse solid cancers.
Read →
Understanding Protein kinases Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding Protein kinases Inhibitors and Methods to Keep Abreast of Their Recent Developments
20 December 2023
Protein kinase inhibitors are drugs that target protein kinases, crucial in cell signaling and regulation. The future sees potential applications in treating various diseases, particularly cancer.
Read →
UNITY Biotechnology Begins Phase 2 ASPIRE Trial Administering UBX1325 to Initial Participants with Diabetic Macular Edema
Latest Hotspot
3 min read
UNITY Biotechnology Begins Phase 2 ASPIRE Trial Administering UBX1325 to Initial Participants with Diabetic Macular Edema
20 December 2023
Biotech company UNITY Biotechnology has launched its Phase 2 ASPIRE trial, administering its aging-focused drug UBX1325 (foselutoclax) to the first patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.